TABLE 5.
Prescription rates of psychopharmaceuticals in male and female forensic in-patients with schizophrenia, separated into first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) as well as oral and depot preparations.
| Men (n = 29) | Women (n = 29) | |||
|
|
|
|||
|
M (SD)/ prevalence in % |
M (SD)/ prevalence in % |
U/χ2 | Significance level (p) | |
| Chlorpromazine/ olanzapine equivalents (oral and depot) |
587.0 (305.3)/19.6 (10.2) | 580.4 (267.7)/19.3 (8.9) | 411.0a | 0.882 |
| Drugs total | 7.506b | 0.585 | ||
| 1–2 | 51.7% | 34.5% | ||
| 3–4 | 34.5% | 44.8% | ||
| >4 | 13.8% | 20.7% | ||
| Psychopharmaceuticals total | 1.303b | 0.861 | ||
| 1–2 | 62.1% | 62.1% | ||
| 3–4 | 34.5% | 34.5% | ||
| >4 | 3.4% | 3.4% | ||
| FGAs total | 0.167b | 0.920 | ||
| 0 | 69.0% | 72.4% | ||
| 1 | 17.2% | 17.2% | ||
| >1 | 13.8% | 10.2% | ||
| FGAs oral | 2.791b | 0.248 | ||
| 0 | 75.9% | 86.2% | ||
| 1 | 24.1% | 10.3% | ||
| >1 | 0.0% | 3.4% | ||
| FGAs depot | 20.7% | 20.7% | 0.000b | 1.000 |
| SGAs total | 2.044b | 0.563 | ||
| 0 | 10.3% | 10.3% | ||
| 1 | 55.2% | 69.0% | ||
| >1 | 34.5% | 20.7% | ||
| SGAs oral | 4.889b | 0.180 | ||
| 0 | 20.7% | 44.8% | ||
| 1 | 55.2% | 44.8% | ||
| >1 | 24.1% | 10.4% | ||
| SGAs depot | 13.8% | 44.8% | 6.740b | 0.009** |
| Depot total | 34.5% | 62.0% | 4.948b | 0.084 |
M, mean; SD, standard deviation; FGAs, first-generation antipsychotics; SGAs, second-generation antipsychotics.
aMann–Whitney-U.
bChi-square χ2 (Pearson).
**p < 0.01 (asymptotic, two-tailed).